Tags » GlaxoSmithKline

"Damn the torpedoes, Full Speed Ahead!"

What does GlaxoSmithKline, the drugs to treat childhood leukemia, malaria, gout, herpes and the compound to prevent organ rejection have in common? The Nobel Laureates Gertrude B. 960 more words

Cancer

UK fraud office expects decision on GSK Case Next Year..

I’m going to make a prediction about this..

I think that the UK Serious Fraud Office will either let GSK off the hook completely (due to some technicality of law or loop-hole) or GSK will get off very lightly (a slap on the wrist). 491 more words

Seroxat

GSK IMPACT Awards 2018 is Open for Application

Deadline: September 22, 2017

Submit applications for a chance to receive the 2018 GSK IMPACT Awards. The GSK IMPACT Awards provide funding and training and development for charities doing excellent work to improve people’s health. 289 more words

SCHOLARSHIPS AND FELLOWSHIPS OPPORTUNITIES

74 Firms going Ex-Dividend next week, including Starbucks, Wal-Mart and Apple

There are several well known large cap stocks going ex-dividend next week including the following twelve Top 100 Dividend Stocks: Valero, IBM, Starbucks, BB&T, Boeing, Diageo, GlaxoSmithKline, Wal-Mart, Apple, Exxon Mobil, UPS and Kroger. 323 more words

Ex-Dividend Dates

GSK delivers further progress in Q2 and sets out new priorities for the Group

Financial highlights

• Pharmaceutical sales, £4.4 billion, +12% AER, +3% CER, Vaccines sales, £1.1 billion, +16% AER, +5% CER, Consumer Healthcare sales, £1.9 billion,+10% AER, flat at CER… 344 more words

Pharmaceutical Stocks Analysis - GSK, Pfizer, Abbott Labs

Since our last bullish outlook on the pharmaceutical sector, Revelation Trading feels that GSK is one stock to look out for. Though it has caused a slight dent, the failure of Congress to repeal and replace Obamacare has not caused the pharmaceutical stocks on our radar to tumble. 253 more words

Revelation Trading

Threat to HIV business spooks GlaxoSmithKline shares

(Source: www.businesstimes.com.sg)

The threat of slowing demand and new competition in GlaxoSmithKline’s flagship HIV drug business unnerved investors in Britain’s biggest drugmaker on Wednesday, sending its shares down as much as 1.8 per cent. 359 more words

Money Matters